Australian biotech market watch 26/06/09

The All Ordinaries has continued its climb out of the mid-week doldrums, lifting by 1.2% today, up nearly 3.5% from its low on Wednesday.

The health indicies have also followed the All Ords, rallying by 1% today, up by 3% since Tuesday.

ResMed enjoyed a hefty lift today of 3.5% to $5.07 after a market analyst gave the stock a four-out-of-five star rating.

CSL (ASX:CSL) continued to put in a strong performance on the back of strong demand for its influenza vaccine products, rising another 22c to $31.99.

Pharmaceutical company, Biota Holdings (ASX:BTA), which is actively involved in influenza research, has also enjoyed a 4.5% gain.

Sonic Healthcare (ASX:SHL) had a big day, rising to its highest price in over a month, reaching $12.23, up 43c.

Acrux (ASX:ACR), shed 2.1% today following a buoyant week in the wake of its announcement of a distribution deal for its Ellavie menopause treatment on Tuesday.

ChemGenex (ASX:CXS) suffered a 6% drop in today's trading, shedding some of its gains over the past several weeks, after announcing an administrative error was responsible for its failure to meet ASX reporting obligations.

Sirtex (ASX:SRX) lost much of its gains from earlier in the week, and has remained fairly stable at $3.51.

Workplace health firm, Konekt, has had a bumpy week, more to do with its low baseline price, lifting from 4c to 6c and back to 5c today.

Cochlear (ASX:COH) moved in line with the market to $58.35, and Ansell (ASX:ANN) recovered much of its losses over the week to end at $9.07.